Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Afamelanotide in EPP
2023-507311-35-00Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Feb 2024
- Modality
- Small Molecules, Peptides
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of Afamelanotide in erythropoietic protoporphyria (EPP), sponsored by Clinuvel Pharmaceuticals. Primary endpoints: Cmax and AUC(0-t). Started Feb 2024; status: completed.
02
Drugs
Afamelanotide
03
Conditions
erythropoietic protoporphyria (EPP)
Beyond the preview
Go deeper on 2023-507311-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507311-35-00.